NSC-CRAd-S-pk7

Phase 1Biologic

NNorthwestern University

NSC-CRAd-S-pk7 is one of 3 biologic programs targeting Glioma, Malignant. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Glioma, MalignantActive, not recruiting

Glioma, MalignantPhase 1

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Glioma, Malignant

#DrugCompanyPhaseTrials

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 2

1 2

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 3

NSC-CRAd-S-pk7

NNorthwestern University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1Active, not recruiting

Glioma, Malignant

NCT06169280

Clinical

Trials by Indication[1]

Glioma, Malignant1 trial

A Phase I Study of Repeated Neural Stem Cell-Based Virotherapy and Standard Radiation and Chemotherapy for Newly Diagnosed High-Grade Glioma

Active, not recruiting·NNorthwestern University·Phase 1·NCT06169280·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NSC-CRAd-S-pk7. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NSC-CRAd-S-pk7 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NSC-CRAd-S-pk7. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Northwestern University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: NNorthwestern University

NSC-CRAd-S-pk7

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Glioma, Malignant1 trial

References

Drug Info

Quick Facts

Related News